353280-77-0

Upstream product

• 122-01-0 4-chloro-benzoyl chloride 
• 13450-77-6 4-chlorohippuric acid 
• 122-51-0 orthoformic acid triethyl ester 

Downstream Products

• 27139-23-7 2-(4-chloro-phenyl)-4-[2-(1-methyl-1H-quinolin-2-ylidene)-ethylidene]-4H-oxazol-5-one 
• 27139-24-8 2-(4-chloro-phenyl)-4-[2-(1-methyl-1H-quinolin-4-ylidene)-ethylidene]-4H-oxazol-5-one 
• 27139-26-0 2-(4-chloro-phenyl)-4-[2-(1-methyl-1H-pyridin-2-ylidene)-ethylidene]-4H-oxazol-5-one 
• 27139-25-9 2-(4-chloro-phenyl)-4-[2-(3-methyl-4-phenyl-3H-thiazol-2-ylidene)-ethylidene]-4H-oxazol-5-one 

Relevant academic research and scientific papers

Syntheses of 5-amino-2-phenyl-4(3H)-pyrimidinone derivertives starting with glycine

N-Cbz derivative of 5-amino-2-phenyl-4(3H)-pyrimidinone was prepared from sodium salt of methyl hydroxymethylene glycinate and benzamidine hydrochloride in good yield. However, the reaction with N-substituted benzamidine did not proceed to give the desired pyrimidinone. In contrast, the reaction of 4-ethoxymethylene-2-phenyl-5(4H)-oxazolone readily prepared from hippuric acid and N-substituted benzamidine proceeded nicely to give 5-(benzoylamino)-6-oxo-2- phenyl-1(6H)-pyrimidineacetic acid in high yield.

PROCESS FOR PRODUCING PYRIMIDINE COMPOUND

Azlactone Compound (2) is reacted with Amidine Compound (3) to give Pyrimidine Compound (1) useful as an intermediate for enzyme inhibitors (e.g., elastase inhibitor, chymase inhibitor etc.): Pyrimidine Compound (1) Azlactone Compound (2) Amidine Compound (3) wherein each symbol is as defined in the specification.

Anthranilate 4H-oxazol-5-ones: Novel small molecule antibacterial acyl carrier protein synthase (AcpS) inhibitors

D-optimal design and Projection to Latent Structures (PLS) analysis were used to optimize screening hit 5 (B. subtilis AcpS IC50: 15 μM, B. subtilis MIC: >200 μM) into a series of 4H-oxazol-5-one, small molecule, antibacterial, AcpS inhibitors. Specifically, 15, 16 and 18 show μM or sub-μM AcpS inhibition (IC50s: 15: 1.1 μM, 16: 1.5 μM, 18: 0.27 μM) and moderate antibacterial activity (MICs: 12.5-50 μM) against B. subtilis, E. faecalis ATCC, E. faecalis VRE and S. pneumo+.